A gene variant near ATM is significantly associated with metformin treatment response in type 2 diabetes: a replication and meta-analysis of five cohorts

A gene variant near ATM is significantly associated with metformin treatment response in type 2 diabetes: a replication and meta-analysis of five cohorts

Show other versions (1)

Bibliografske podrobnosti
Main Authors:	van Leeuwen, N, Nijpels, G, Becker, M, Deshmukh, H, Zhou, K, Stricker, B, Uitterlinden, A, Hofman, A, van 't Riet, E, Palmer, C, Guigas, B, Slagboom, P, Durrington, P, Calle, R, Neil, A, Hitman, G, Livingstone, S, Colhoun, H, Holman, R, McCarthy, M, Dekker, J, 't Hart, L, Pearson, E
Format:	Journal article
Izdano:	2012

Podobne knjige/članki

A gene variant near ATM is significantly associated with metformin treatment response in type 2 diabetes: a replication and meta-analysis of five cohorts.
od: van Leeuwen, N, et al.
Izdano: (2012)

A gene variant near ATM is significantly associated with metformin treatment response in type 2 diabetes: a replication and meta-analysis of two Dutch and two UK cohorts
od: 't Hart, L, et al.
Izdano: (2011)

The role of ATM in response to metformin treatment and activation of AMPK.
od: Zhou, K, et al.
Izdano: (2012)

Rapid emergence of effect of atorvastatin on cardiovascular outcomes in the Collaborative Atorvastatin Diabetes Study (CARDS).
od: Colhoun, H, et al.
Izdano: (2005)

Effect of atorvastatin on stroke in the collaborative atorvastatin diabetes study (CARDS): Factors predictive of the risk of stroke
od: Newman, C, et al.
Izdano: (2005)

Baseline characteristics in the Collaborative AtoRvastatin Diabetes Study (CARDS) in patients with Type 2 diabetes.
od: Thomason, M, et al.
Izdano: (2004)

Stroke prediction and stroke prevention with atorvastatin in the Collaborative Atorvastatin Diabetes Study (CARDS).
od: Hitman, G, et al.
Izdano: (2007)

Effect of atorvastatin in patients 65 years of age with type 2 diabetes: Subgroup analysis from the collaborative atorvastatin diabetes study (CARDS)
od: DeMicco, D, et al.
Izdano: (2005)

Analysis of efficacy and safety in patients aged 65-75 years at randomization: Collaborative Atorvastatin Diabetes Study (CARDS).
od: Neil, H, et al.
Izdano: (2006)

Effect of atorvastatin on stroke in patients with type 2 diabetes: factors predicting the risk of stroke in the Collaborative Atorvastatin Diabetes Study (CARDS)
od: Hitman, G, et al.
Izdano: (2005)

Effects of atorvastatin on kidney outcomes and cardiovascular disease in patients with diabetes: an analysis from the Collaborative Atorvastatin Diabetes Study (CARDS).
od: Colhoun, H, et al.
Izdano: (2009)

Total soluble and endogenous secretory receptor for advanced glycation end products as predictive biomarkers of coronary heart disease risk in patients with type 2 diabetes: an analysis from the CARDS trial.
od: Colhoun, H, et al.
Izdano: (2011)

Cost-effectiveness of primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes: results from the Collaborative Atorvastatin Diabetes Study (CARDS).
od: Raikou, M, et al.
Izdano: (2007)

Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial.
od: Colhoun, H, et al.
Izdano: (2004)

Change in Lp-PLA2 With Risk Change on Statin Therapy in the Collaborative Atorvastatin Diabetes Study (CARDS)
od: Betteridge, D, et al.
Izdano: (2009)

Role of Mitochondria in the Mechanism(s) of Action of Metformin
od: Guillaume Vial, et al.
Izdano: (2019-05-01)

Heritability of variation in glycaemic response to metformin: a genome-wide complex trait analysis.
od: Zhou, K, et al.
Izdano: (2014)

Common variants near ATM are associated with glycemic response to metformin in type 2 diabetes.
od: Zhou, K, et al.
Izdano: (2011)

Common variants near ATM are associated with glycemic response to metformin in type 2 diabetes
od: Zhou, K, et al.
Izdano: (2011)

Erratum: Apolipoproteins, cardiovascular risk and statin response in type 2 diabetes: The Collaborative Atorvastatin Diabetes Study (CARDS)
od: Charlton-Menys, V, et al.
Izdano: (2009)

Design of the Collaborative AtoRvastatin Diabetes Study (CARDS) in patients with type 2 diabetes.
od: Colhoun, H, et al.
Izdano: (2002)

Apolipoproteins, cardiovascular risk and statin response in type 2 diabetes: the Collaborative Atorvastatin Diabetes Study (CARDS).
od: Charlton-Menys, V, et al.
Izdano: (2009)

Targets of statin therapy: LDL cholesterol, non-HDL cholesterol, and apolipoprotein B in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS).
od: Charlton-Menys, V, et al.
Izdano: (2009)

Heritability of variation in glycaemic response to metformin: A genome-wide complex trait analysis
od: Zhou, K, et al.
Izdano: (2014)

Cost-effectiveness of atorvastatin (10mg) in patients with type 2 diabetes without coronary heart disease: CARDS trial analysis and extrapolation
od: Raikou, M, et al.
Izdano: (2005)

The safety and tolerability of atorvastatin 10 mg in the Collaborative Atorvastatin Diabetes Study (CARDS).
od: Newman, C, et al.
Izdano: (2008)

Safety of atorvastatin in the collaborative AtoRvastatin diabetes study (CARDS)
od: Newman, C, et al.
Izdano: (2006)

C-reactive Protein and Amyloid A as Predictors of Cardiovascular Events in Type 2 Diabetes in CARDS
od: Charlton-Menys, V, et al.
Izdano: (2009)

Alterations in cellular energy metabolism associated with the antiproliferative effects of the ATM inhibitor KU-55933 and with metformin.
od: Mahvash Zakikhani, et al.
Izdano: (2012-01-01)

The effect of atorvastatin on serum lipids, lipoproteins and NMR spectroscopy defined lipoprotein subclasses in type 2 diabetic patients with ischaemic heart disease.
od: Soedamah-Muthu, S, et al.
Izdano: (2003)

Metformin and mortality. Reply to Lund SS [letter]
od: Stevens, R, et al.
Izdano: (2013)

Metformin and mortality. Reply to Lund SS [letter].
od: Stevens, R, et al.
Izdano: (2013)

The effect of atorvastatin therapy on tumour necrosis factor-α and vascular adhesion molecules in patients with type 2 diabetes mellitus with no prior history of coronary heart disease
od: Soedamah-Muthu, S, et al.
Izdano: (2011)

Metformin and risk of cardiovascular disease.
od: Turner, R, et al.
Izdano: (1999)

Risk of anaemia with long-term metformin use in a community setting
od: Donnelly, L, et al.
Izdano: (2017)

The sustained influence of metformin therapy on circulating GLP-1 levels in individuals with and without type 2 diabetes
od: Preiss, D, et al.
Izdano: (2016)

ANALISIS TERHADAP PERLINDUNGAN HUKUM BAGI NASABAH PENGGUNA ATM (SKIMMING KARTU ATM PADA MESIN ATM BANK X)
od: , Ronald Arthur Saiya, et al.
Izdano: (2014)

Identifying the Latitude and Longitude of ATMs in ATM Networks
od: Niloofar Haghjoo, et al.
Izdano: (2024-06-01)

The C Allele of ATM rs11212617 Associates With Higher Pathological Complete Remission Rate in Breast Cancer Patients Treated With Neoadjuvant Metformin
od: Elisabet Cuyàs, et al.
Izdano: (2019-03-01)

METFORMIN IN THE MANAGEMENT OF TYPE-2 DIABETES - REPLY
od: Holman, R, et al.
Izdano: (1989)